Regeneron's acquisition of hearing loss company Decibel was de-risked by a long-term collaboration with its own Genetics Center (RGC). The RGC acted as an internal engine, feeding data and validating assumptions behind Decibel's gene therapy target for years. This deep scientific due diligence enabled a confident acquisition.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

To reach its goal of 20 million sequenced individuals, Regeneron plans to use tokenization to link de-identified EHR data from one source (like a hospital) with biospecimens from another (like LabCorp). This strategy moves beyond single-institution collaborations to massively scale its ability to create linked datasets.

To overcome the scaling challenges of traditional biobanks, Regeneron is pioneering a new model. They partner with companies specializing in aggregating de-identified health records and, separately, with groups handling bio-sampling. This "uncoupled" approach allows them to link massive, independent data streams to achieve unprecedented scale.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

To scale its database from millions to tens of millions, Regeneron is moving beyond bespoke global studies. The new model involves large-scale partnerships with health systems and consumer data sources, using privacy-preserving tokenization to securely link genetic data with vast electronic health records.

Regeneron's genetics engine created so many new targets that it revealed a strategic weakness: two-thirds were intracellular and untreatable with its world-class antibody platform. This success forced the company to "reinvent itself" and invest heavily in new modalities like sRNA and gene therapy to capitalize on its own discoveries.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.